Radiopharmaceuticals Market USD 350 Million by 2020

Radiopharmaceuticals Market 2013-2020 report estimates the global radiopharmaceuticals market to reach nearly USD 350 Million in 2020, at a CAGR of 4.9% from 2016 to 2020 - iHealthcareAnalyst, Inc.

Visit the Radiopharmaceuticals Market 2013-2020 report https://www.ihealthcareanalyst.com/report/radiopharmaceuticals-market/

Medicinal radiocompounds or radiopharmaceuticals are a group of pharmaceutical drugs which have radioactivity and they can be used as diagnostic and therapeutic agents. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood and tumors, and in therapy for many diseases.

The global radiopharmaceuticals market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the indications (cardiovascular, oncology, neurological, thyroid, gastrointestinal, etc.), therapeutics (systemic oncology using Iodine, Yttrium, Samarium, Strontium, Rhenium, Lutetium, Erbium; cardiology, neurology, etc.), technologies (SPECT – Technetium, Thallium, Gallium, Iodine, Rhenium, Yttrium; PET - Fludeoxyglucose, Rubidium, Carbon-11 Choline, Nitrogen-13 Ammonia, etc.), generators (Mo-99/Tc-99m, Sr-82/Rb-82, Ge-68/Ga-68, Sr-90/Y-90, and W-188/Re-188 generators), end users (diagnostic centers, hospitals and medical centers), and forecasts growth trends (CAGR% - 2016 to 2020).

The global radiopharmaceuticals market report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.

1. Indication
1.1. Cardiovascular
1.2. Oncology
1.3. Others (Neurological, Thyroid, Gastrointestinal)

2. Therapy
2.1. Systemic Oncology
2.1.1. Iodine (I-131)
2.1.2. Yttrium (90Y)
2.1.3. Samarium (Sm-153)
2.1.4. Strontium (89Sr)
2.1.5. Rhenium (186Re)
2.1.6. Lutetium (Lu-177)
2.1.7. Erbium (169Er)
2.1.8. Others
2.2. Others (Cardiology, Neurology)

3. Technology
3.1. Single-Photon Emission Computed Tomography (SPECT)
3.1.1. Technetium (Tc-99m)
3.1.2. Thallium (TI-201)
3.1.3. Gallium (Ga-67)
3.1.4. Iodine (I-123)
3.1.5. Rhenium (Re-186)
3.1.6. Yttrium (Y-90)
3.1.7. Others
3.2. Positron Emission Tomography (PET)
3.2.1. Fludeoxyglucose (18F-FDG)
3.2.2. Rubidium (Rb-82)
3.2.3. Others (Carbon-11 Choline, Nitrogen-13 Ammonia)

4. Generator Type
4.1. Mo-99/Tc-99m Generator
4.2. Sr-82/Rb-82 Generator
4.3. Ge-68/Ga-68 Generator
4.4. Sr-90/Y-90 Generator
4.5. W-188/Re-188 Generator

5. End User
5.1. Diagnostic Centers
5.2. Hospitals & Medical Centers

6. Company Profiles
6.1. Cardinal Health Inc.
6.2. Covidien Plc
6.3. GE Healthcare
6.4. IBA Group
6.5. Lantheus Medical Imaging
6.6. Monrol Nuclear Products, Inc.
6.7. Nordion, Inc.
6.8. NTP Radioisotopes Ltd.
6.9. Polatom
6.10. Positron Corporation
6.11. Siemens Healthcare

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.